RESULTS FOR : 'Pharmacogenomics'
Showing 1 to 2 of 2 results |    
Keyword Search
Show#
Show#
Results Category/Section
Reigniting pharmaceutical innovation through holistic drug targeting

Modern drug discovery approaches take too long, are too expensive, have too many clinical failures and uncertain outcomes. There are many reasons for this unsustainable business model, but primarily, the approaches are not comprehensively holistic.

With synthetic biology, drug discovery is going virtual.

Christopher Voigt is a professor of biological engineering at the Massachusetts Institute of Technology, where his lab focuses on synthetic biology. Two major areas of interest for him are developing a genetic programming language for cells and applying synthetic biology to biotechnology challenges.